Table 1

Clinical data of four patients with generalised gravis and SARS-CoV-2

Patient	1	2	3	4
Disease duration	6 years	4 years	2 years	3 years
MGFA classification	IIa	IIIb	IIa	V
Thymectomy	Yes	Yes	No	Yes
AB status	Anti-ACh-Rab	Anti-ACh-Rab	Negative	Anti-ACh-Rab
Main symptoms prior to admission	Ocular, bulbar, lower limb weakness.	Respiratory muscles, limb weakness.	Unilateral ptosis, double vision.	Ocular (double vision).
Comorbidities	M Basedow (resolved in 2015).	Behçet‘s disease, chronic migraine, hypogonadotrope hypogonadism, hypothyroidism, obesity, thymoma.	Arterial hypertension.	Obesity, left phrenic nerve damage, sleep apnoea.
MG baseline treatment	AZA 50 mg/day, pyridostigmine 60 mg 5–6×/day.	Pyridostigmine 60 mg 4–5×/day, prednisone 25 mg/day, subcutaneous immunoglobulins 12 g every 4 days.	Pyridostigmine 3×30 mg/day.	Pyridostigmine 60 mg 3×/day, rituximab 1 g every 6 months.
MG treatment change	AZA stopped during COVID-19; IVIG 5 days.	None.	None.	Pyridostigmine increased to 360 mg/day.
COVID-19 disease course	Anosmia after 4 weeks.	Fluctuating headaches and respiratory symptoms over 6 weeks.	Fully recovered after around 3 weeks.	Mechanical ventilation >14 days, tracheostoma for 9 weeks.

AZA, azathioprine; IVIG, intravenous immunoglobulin; MG, myasthenia gravis; MGFA, Myasthenia Gravis Foundation of America; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.